NasdaqGS - Nasdaq Real Time Price • USD
Biogen Inc. (BIIB)
As of 9:45 AM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 27 | 27 | 31 | 32 |
| Avg. Estimate | 3.97 | 3.97 | 15.56 | 17.45 |
| Low Estimate | 3.4 | 3.01 | 14.91 | 13.76 |
| High Estimate | 6.04 | 4.29 | 16.37 | 21.11 |
| Year Ago EPS | 4.02 | 4.36 | 14.72 | 15.56 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 25 | 24 | 32 | 32 |
| Avg. Estimate | 2.37B | 2.4B | 9.48B | 9.54B |
| Low Estimate | 2.32B | 2.31B | 8.98B | 8.59B |
| High Estimate | 2.43B | 2.5B | 9.69B | 11.45B |
| Year Ago Sales | 2.37B | 2.53B | 9.84B | 9.48B |
| Sales Growth (year/est) | 0.30% | -5.20% | -3.70% | 0.60% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | 3.77 | 3.97 | 3.18 | 3.45 |
| EPS Actual | 4.02 | 4.36 | 3.3 | 3.67 |
| Difference | 0.25 | 0.39 | 0.12 | 0.22 |
| Surprise % | 6.60% | 9.80% | 3.80% | 6.40% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 3.97 | 3.97 | 15.56 | 17.45 |
| 7 Days Ago | 3.94 | 3.98 | 15.44 | 17.45 |
| 30 Days Ago | 3.94 | 4 | 15.48 | 17.62 |
| 60 Days Ago | 3.95 | 3.99 | 15.48 | 17.78 |
| 90 Days Ago | 3.89 | 4.25 | 15.68 | 18.44 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 9 | 9 | 17 | 10 |
| Up Last 30 Days | 14 | 11 | 17 | 11 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 9 | 11 | 4 | 12 |
Growth Estimates
| CURRENCY IN USD | BIIB | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -1.20% | -- | -- | 1.50% |
| Next Qtr. | -8.90% | -- | -- | 11.40% |
| Current Year | 5.70% | -- | -- | 5.20% |
| Next Year | 12.10% | -- | -- | 13.40% |
| Next 5 Years (per annum) | 2.80% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -18.06% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Wedbush: Neutral to Neutral | 4/25/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 4/25/2024 |
| Reiterates | Needham: Buy to Buy | 4/25/2024 |
| Reiterates | Needham: Buy to Buy | 4/24/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 4/19/2024 |
| Maintains | Wedbush: Neutral to Neutral | 4/17/2024 |
Related Tickers
GILD Gilead Sciences, Inc.
67.09
+0.01%
AMGN Amgen Inc.
272.55
-0.17%
BMY Bristol-Myers Squibb Company
46.39
-5.07%
LLY Eli Lilly and Company
726.31
-0.80%
NVS Novartis AG
98.83
+0.49%
PFE Pfizer Inc.
26.14
-0.51%
ABBV AbbVie Inc.
168.12
+0.19%
JNJ Johnson & Johnson
147.65
-0.60%
MRK Merck & Co., Inc.
132.33
+4.19%
AZN AstraZeneca PLC
75.50
+6.04%